Home
About
Overview
Sharing Data
ORCID
Help
History (1)
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
See All Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis.
Two-year Efficacy and Safety of Subcutaneous Tocilizumab in Combination with Disease-modifying Antirheumatic Drugs Including Escalation to Weekly Dosing in Rheumatoid Arthritis. J Rheumatol. 2018 04; 45(4):456-464.
View in:
PubMed
subject areas
Adult
Adult
Aged
Aged
Antibodies, Monoclonal, Humanized
Antibodies, Monoclonal, Humanized
Antirheumatic Agents
Antirheumatic Agents
Arthritis, Rheumatoid
Arthritis, Rheumatoid
Dose-Response Relationship, Drug
Dose-Response Relationship, Drug
Double-Blind Method
Double-Blind Method
Drug Therapy, Combination
Drug Therapy, Combination
Drug Tolerance
Drug Tolerance
Female
Female
Follow-Up Studies
Follow-Up Studies
Humans
Humans
Injection Site Reaction
Injection Site Reaction
Injections, Subcutaneous
Injections, Subcutaneous
Male
Male
Middle Aged
Middle Aged
Remission Induction
Remission Induction
Severity of Illness Index
Severity of Illness Index
Treatment Outcome
Treatment Outcome
authors with profiles
Joan Merrill